Previous research has indicated the potential value of docetaxel in treating NPC (26), and our study further suggested that targeting ACTRIIB's N-glycosylation could enhance the efficacy of docetaxel, offering a potential combined therapy approach. This evidence concerns the gene ACVR2B and nasopharyngeal carcinoma.